SCHEMBL863371

SCHEMBL863371

CNc1nc2c(Cl)cccc2cc1[C@H](C)Nc1ncnc2[nH]cnc12

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 15/20 0.54
PIK3CG P48736 6/20 0.39
PIK3R1 P27986 5/20 0.39
PIK3CB P42338 4/20 0.39
PIK3CA P42336 3/20 0.39
ABCB11 O95342 1/20 0.39
TBXA2R P21731 1/20 0.39
HTR2A P28223 1/20 0.39
PDE3A Q14432 1/20 0.39
AURKA O14965 1/20 0.37
RPS6KB1 P23443 1/20 0.37
AURKB Q96GD4 1/20 0.37
EGFR P00533 2/20 0.37
KRAS P01116 2/20 0.36
SOS1 Q07889 1/20 0.36
AXL P30530 1/20 0.35
MERTK Q12866 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863372 1.00 PIK3CD (0.54) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA
SCHEMBL863329 0.87 PIK3CD (0.50) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA
SCHEMBL863330 0.87 PIK3CD (0.50) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA
SCHEMBL863661 0.87 PIK3CD (0.48) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA
SCHEMBL863660 0.87 PIK3CD (0.48) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA
SCHEMBL864803 0.86 PIK3CD (0.49) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA
SCHEMBL864804 0.86 PIK3CD (0.49) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA
SCHEMBL864096 0.86 PIK3CD (0.48) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA
SCHEMBL864097 0.86 PIK3CD (0.48) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA
SCHEMBL864038 0.86 PIK3CD (0.49) PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396315-B1 QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-08-31 EP disclosed
US-8513284-B2 Fused pyridine and pyrazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2013-08-20 US disclosed
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors PDPK1, PDXK, PIK3CA PIK3CD 14/4885PIK3CG 21/4885PIK3R1 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.